01495nas a2200241   4500000000100000000000100001008004100002260002700043100002200070700001900092700002100111700001700132700001900149700002200168700001900190700002100209700001700230700001900247245003600266856004600302520088300348020002201231       2022                            d  c2022/04/27bIntechOpen1 aAnubhab Mukherjee1 aAprajita Sinha1 aMaheshree Maibam1 aBharti Bisht1 aManash K. Paul1 aAnubhab Mukherjee1 aAprajita Sinha1 aMaheshree Maibam1 aBharti Bisht1 aManash K. Paul00aOrganoids and Commercialization  uhttps://www.intechopen.com/chapters/815473 aOrganoids are 3D miniature tissue mimics and have been effectively used for various purposes, including disease modeling, various drug screening, mechanism of pathogenesis, stem cell research, and tumor immunology. Organoids are as varied as the body’s tissues and organs and have enormous economic potential. They can open new ways to tailored therapy and precision medicine. In clinical investigations, patient-derived organoids have been used to predict patient responses to therapeutic regimens and perhaps improve cancer treatment outcomes. Recent developments in stem cell research and genomic technologies have led to breakthrough innovations in organoid bioengineering, large-scale manufacturing, biobanking, and commercialization. This chapter reviews the notion of organoid biobanking, companies involved and the commercialization aspect, and ethical considerations.  a978-1-80355-769-4